{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:59:20Z","timestamp":1781521160992,"version":"3.54.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0188375","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T13:35:00Z","timestamp":1511184900000},"page":"e0188375","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5112-6955","authenticated-orcid":true,"given":"Mi-yeon","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Suk","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1185-2631","authenticated-orcid":true,"given":"Ho Jun","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"HN Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0272-6386(88)80023-4","article-title":"Clinical features and natural history in adults with IgA nephropathy","volume":"12","author":"G D'Amico","year":"1988","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"ref3","first-page":"353","article-title":"Clinical features and natural history of IgA nephropathy","volume":"12","author":"I Rychlik","year":"1999","journal-title":"Ann Med Interne"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/sj.ki.5000419","article-title":"Treatment of IgA nephropathy","volume":"69","author":"J Barratt","year":"2006","journal-title":"Kidney Int"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"PK-T Li","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11255-012-0313-y","article-title":"Mycophenolic acid reverses IgA1 aberrant glycosylation through up-regulating Cosmc expression in IgA nephropathy","volume":"45","author":"L Xie","year":"2013","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/ndt\/gfm781","article-title":"External suppression causes the low expression of the Cosmc gene in IgA nephropathy","volume":"23","author":"W Qin","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3109\/0886022X.2016.1148936","article-title":"Tacrolimus restores podocyte injury and stabilizes the expression of Cabin1 in 5\/6 nephrectomized rats","volume":"38","author":"Y Wen","year":"2016","journal-title":"Ren Fail"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"e106164","DOI":"10.1371\/journal.pone.0106164","article-title":"The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4","volume":"9","author":"L Peng","year":"2014","journal-title":"PloS One"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"e0137049","DOI":"10.1371\/journal.pone.0137049","article-title":"Angiopoietin-Like-4, a Potential Target of Tacrolimus, Predicts Earlier Podocyte Injury in Minimal Change Disease","volume":"10","author":"J-S Li","year":"2015","journal-title":"PloS One"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00467-003-1370-3","article-title":"Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome","volume":"19","author":"K Loeffler","year":"2004","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000337175","article-title":"Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy","volume":"35","author":"Q Zhang","year":"2012","journal-title":"Am J Nephrol"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"e71545","DOI":"10.1371\/journal.pone.0071545","article-title":"Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy","volume":"8","author":"Y-C Kim","year":"2013","journal-title":"PloS One"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12882-017-0467-z","article-title":"Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis","volume":"18","author":"Y-H Song","year":"2017","journal-title":"BMC Nephrol"},{"issue":"35","key":"ref16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004731","article-title":"The effect of calcineurin inhibitors in the treatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA)","volume":"95","author":"W Peng","year":"2016","journal-title":"Medicine"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1681\/ASN.2009121253","article-title":"Activation of NFAT signaling in podocytes causes glomerulosclerosis","volume":"21","author":"Y Wang","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1210\/me.2011-0029","article-title":"Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo","volume":"25","author":"L Wang","year":"2011","journal-title":"Mol Endocrinol"},{"issue":"196","key":"ref19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-642-00663-0_5","article-title":"Mechanisms of drug-induced nephrotoxicity","author":"TD Nolin","year":"2010","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ki.1995.200","article-title":"Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation","volume":"47","author":"SC Textor","year":"1995","journal-title":"Kidney Int"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/00007890-199306000-00023","article-title":"Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients","volume":"55","author":"SC Textor","year":"1993","journal-title":"Transplantation"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1159\/000187876","article-title":"FK 506 for vascular permeability factor production in minimal change nephrotic syndrome","volume":"66","author":"K Maruyama","year":"1994","journal-title":"Nephron"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00011-015-0893-y","article-title":"FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats","volume":"65","author":"X-M Qi","year":"2016","journal-title":"Inflamm Res"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"e12679","DOI":"10.14814\/phy2.12679","article-title":"Role of calcineurin (CN) in kidney glomerular podocyte: CN inhibitor ameliorated proteinuria by inhibiting the redistribution of CN at the slit diaphragm","volume":"4","author":"A Wakamatsu","year":"2016","journal-title":"Physiol Rep"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"M Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11255-012-0205-1","article-title":"Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial","volume":"45","author":"L Fan","year":"2013","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/labinvest.2015.93","article-title":"Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury","volume":"95","author":"SW Lim","year":"2015","journal-title":"Lab Invest"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/lt.20065","article-title":"A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation","volume":"10","author":"CE Staatz","year":"2004","journal-title":"Liver Transpl."},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10157-015-1223-y","article-title":"Evidence-based clinical practice guidelines for IgA nephropathy 2014","volume":"20","author":"Y Yuzawa","year":"2016","journal-title":"Clin Exp Nephrol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0192266","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0188375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T06:51:09Z","timestamp":1570344669000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0188375"}},"subtitle":[],"editor":[{"given":"Paolo","family":"Cravedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0188375","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0192266","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,20]]}}}